SAKK 36/13 Study: Treatment of mantle cell lymphoma with ibrutinib and bortezomib is highly effective.

Each year, approximately 80 people in Switzerland receive a diagnosis of mantle cell lymphoma. This is a malignant disease of the lymphatic system. In case of relapse or insufficient response to standard therapies, these patients have an unfavorable prognosis.

SAKK 36/13 Study: Treatment of mantle cell lymphoma with ibrutinib and bortezomib is highly effective.

Each year, approximately 80 people in Switzerland receive a diagnosis of mantle cell lymphoma. This is a malignant disease of the lymphatic system. In case of relapse or insufficient response to standard therapies, these patients have an unfavorable prognosis.

For this situation, the SAKK 36/13 study investigated a new therapy. We demonstrate that it is feasible and safe to combine ibrutinib with bortezomib, and that this targeted combination was able to control the disease in > 80% at this stage. The observed effect has attracted widespread interest mainly in patients with particularly unfavorable disease factors. A total of 58 patients were included in this international study.

Graphic high risk disease
This combination therapy does not result in significant early event-free survival in patients with high-risk disease.

Full publication in eClinicalMedicine

All News
27 September 2023